PRINCETON, N.J.–(BUSINESS WIRE)–Oct. 15, 2024– UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug…Original Article
You may also like
UroGen Submits Completed UGN-102 NDA Seeking Approval...
FDA Accepts LEO Pharma’s Filing of Delgocitinib...
Iterum Therapeutics Provides Update on FDA Advisory...
AbbVie Submits Biologics License Application to the...
PTC Therapeutics Announces FDA Acceptance for Filing...
U.S. Food and Drug Administration (FDA) Accepts New...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.